Platinum Chemotherapy Hypersensitivity
Authors:
- 1 November 2017
- journal article
- review article
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 37 (4) , 663-677
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactionsBritish Journal of Cancer, 2013
- A Rational Approach to the Management of Recurrent or Persistent Ovarian CarcinomaClinical Obstetrics and Gynecology, 2012
- Ovarian CancerClinical Obstetrics & Gynecology, 2012
- Current Surgical Management of Ovarian CancerHematology/Oncology Clinics of North America, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Incidence of Carboplatin-Related Hypersensitivity Reactions in Japanese Patients With Gynecologic MalignanciesInternational Journal of Gynecological Cancer, 2009
- Pharmaceutical Management of Ovarian CancerDrugs, 2008
- Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' HospitalGynecologic Oncology, 2007
- Carboplatin Skin Testing: A Skin-Testing Protocol for Predicting Hypersensitivity to Carboplatin ChemotherapyJournal of Clinical Oncology, 2001
- Clinical Features of Hypersensitivity Reactions to CarboplatinJournal of Clinical Oncology, 1999